Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer - Sun, T Y; Niu, X; Chakraborty, A; Neal, J W; Wakelee, H A (J Thorac Oncol, 2019)